TGFB1 and acute myeloid leukemia: The EVs from AML-MSCs (AML-MSC-EVs) protect AML cells against cytarabine or AC220 (FLT3 kinase suppressor) and contain higher levels of well-known clinical risk factors, such as transforming growth factor-β1 (TGF-β1) and miR-155, compared to EVs from healthy donors [47].